Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05545969
Title Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia

mucosal melanoma


Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.